MERCK KGAA SAYS CILENGITIDE PHASE III TRIAL MISSES ENDPOINT(ENG)

     (The following press release from Merck KGaA was received by e-mail. It 
was not confirmed by the sender.) 
News Release 
Your Contact
Phyllis Carter
Phone .+49 6151 72-3321 
Merck: Phase III Trial of Cilengitide Did Not Meet Primary Endpoint in
Patients With Newly Diagnosed Glioblastoma 
• Patients with newly diagnosed glioblastoma and methylated MGMT gene
  promoter status did not live significantly longer when treated with
  cilengitide plus chemoradiotherapy 
Darmstadt, Germany, February 25, 2013 – Merck announced today that the
Phase III CENTRIC(a) trial of the investigational integrin inhibitor
cilengitide did not meet its primary endpoint of significantly increasing
overall survival when added to the current standard chemoradiotherapy
regimen (temozolomide and radiotherapy). CENTRIC includes patients with
newly diagnosed glioblastoma and methylated O(6)-methylguanine-DNA
methyltransferase (MGMT) gene promoter status. The trial was planned and is
being conducted in partnership with the European Organisation for Research
and Treatment of Cancer (EORTC). Detailed trial results will be submitted
for presentation at the American Society of Clinical Oncology (ASCO) 2013
Annual Meeting and publication in a peer-reviewed journal. 
The complete news release can be downloaded at the following link:
http://news.merck.de/N/0/BE2FE07AD630830EC1257B1D001F007B/$File/CENTRIC-E.pdf 
News releases from Merck KGaA, Darmstadt, Germany, are available at this
address:
www.merckgroup.com/media or for residents in the USA and Canada at
www.emdgroup.com/media 
In case you are a resident of the USA or Canada please go to
http://www.emdgroup.com/subscribe to register again for your online
subscription of this service as our newly introduced geo-targeting requires
new links in the email. 
You may change your subscription at any time by following either one of the
following links:
www.merckgroup.com/subscribe or www.emdgroup.com/subscribe
And please feel free to unsubscribe this service with either
www.merckgroup.com/subscribe or www.emdgroup.com/unsubscribe
Thank you very much! 
Merck KGaA ,Darmstadt, Germany
External Communications
E-mail: Media.Relations@merck.de
Hotline: +49 (0) 6151/72-5000 
This message and any attachment are confidential and may be privileged or
otherwise protected from disclosure. If you are not the intended recipient,
you must not copy this message or attachment or disclose the contents to
any other person. If you have received this transmission in error, please
notify the sender immediately and delete the message and any attachment
from your system. Merck KGaA, Darmstadt, Germany and any of its
subsidiaries do not accept liability for any omissions or errors in this
message which may arise as a result of E-Mail-transmission or for damages
resulting from any unauthorized changes of the content of this message and
any attachment thereto. Merck KGaA, Darmstadt, Germany and any of its
subsidiaries do not guarantee that this message is free of viruses and does
not accept liability for any damages caused by any virus transmitted
therewith. 
Click http://disclaimer.merck.de to access the German, French, Spanish and
Portuguese versions of this disclaimer.
 
 
Press spacebar to pause and continue. Press esc to stop.